{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:21:31Z","timestamp":1773364891089,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1007\/s11936-005-0001-7","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T09:30:07Z","timestamp":1180863007000},"page":"3-13","source":"Crossref","is-referenced-by-count":4,"title":["Current treatment options for CHF management: Focus on the renin-angiotensin-aldosterone system"],"prefix":"10.1007","volume":"7","author":[{"given":"Olaf","family":"Hedrich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard D.","family":"Patten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"De Nofrio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1_CR1","volume-title":"2002 Heart and Stroke Statistical Update","author":"American Heart Association","year":"2003","unstructured":"American Heart Association: 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2003."},{"key":"1_CR2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1161\/01.HYP.1.3.274","volume":"1","author":"SA Atlas","year":"1979","unstructured":"Atlas SA, Case DB, Sealey JE, et al.: Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 1979, 1:274\u2013280.","journal-title":"Hypertension"},{"key":"1_CR3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199606203342507","volume":"334","author":"TL Goodfriend","year":"1996","unstructured":"Goodfriend TL, Elliott ME, Catt KJ: Angiotensin receptors and their antagonists. N Engl J Med 1996, 334:1649\u20131654.","journal-title":"N Engl J Med"},{"key":"1_CR4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(99)10365-9","volume":"355","author":"M Burnier","year":"2000","unstructured":"Burnier M, Brunner H: Angiotensin II receptor antagonists. Lancet 2000, 355:637\u2013645.","journal-title":"Lancet"},{"key":"1_CR5","first-page":"H1769","volume":"273","author":"E Balcells","year":"1997","unstructured":"Balcells E, Meng QC, Johnson WH Jr, et al.: Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997, 273:H1769-H1774.","journal-title":"Am J Physiol"},{"key":"1_CR6","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1161\/01.HYP.33.6.1399","volume":"33","author":"M Ihara","year":"1999","unstructured":"Ihara M, Urata H, Kinoshita A, et al.: Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999, 33:1399\u20131405.","journal-title":"Hypertension"},{"key":"1_CR7","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/00005344-198211000-00014","volume":"4","author":"J Biollaz","year":"1982","unstructured":"Biollaz J, Brunner HR, Gavras I, et al.: Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982, 4:966\u2013972.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1_CR8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/01.RES.73.3.413","volume":"73","author":"J Sadoshima","year":"1993","unstructured":"Sadoshima J, Izumo S: Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype. Circ Res 1993, 73:413\u2013423.","journal-title":"Circ Res"},{"key":"1_CR9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1172\/JCI119531","volume":"100","author":"HM Siragy","year":"1997","unstructured":"Siragy HM, Carey RM: The subtype 2 (AT2) angiotensin receptor mediated renal production of nitric oxide in conscious rats. J Clin Invest 1997, 100:264\u2013269.","journal-title":"J Clin Invest"},{"key":"1_CR10","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1073\/pnas.96.11.6506","volume":"96","author":"HM Siragy","year":"1999","unstructured":"Siragy HM, Inagami T, Ichiki T, Carey RM: Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci U S A 1999, 96:6506\u20136510.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11936-004-0033-4","volume":"6","author":"RD Patten","year":"2004","unstructured":"Patten RD, Soman P: Prevention and reversal of LV remodeling with neurohormonal inhibitors. Curr Treat Options Cardiovasc Med 2004, 6:313\u2013325. An excellent review of this topic presented in a managementbased format.","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"1_CR12","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1006\/jmcc.1998.0775","volume":"30","author":"T Tamura","year":"1998","unstructured":"Tamura T, Onodera T, Said S, Gerdes AM: Correlation of myocyte lengthening to chamber dilation in the spontaneously hypertensive heart failure (SHHF) rat. J Mol Cell Cardiol 1998, 30:2175\u20132181.","journal-title":"J Mol Cell Cardiol"},{"key":"1_CR13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0022-2828(08)80028-4","volume":"27","author":"CA Beltrami","year":"1995","unstructured":"Beltrami CA, Finato N, Rocco M, et al.: The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol 1995, 27:291\u2013305.","journal-title":"J Mol Cell Cardiol"},{"key":"1_CR14","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/01.CIR.101.10.1130","volume":"101","author":"H Kawano","year":"2000","unstructured":"Kawano H, Do YS, Kawano Y, et al.: Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000, 101:1130\u20131137.","journal-title":"Circulation"},{"key":"1_CR15","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","volume":"83","author":"KT Weber","year":"1991","unstructured":"Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium: fibrosis and the renin-angiotensinaldosterone system. Circulation 1991, 83:1849\u20131865.","journal-title":"Circulation"},{"key":"1_CR16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.RES.71.3.503","volume":"71","author":"M Lombes","year":"1992","unstructured":"Lombes M, Oblin ME, Gasc JM, et al.: Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992, 71:503\u2013510.","journal-title":"Circ Res"},{"key":"1_CR17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/01.CIR.103.1.72","volume":"103","author":"Y Mizuno","year":"2001","unstructured":"Mizuno Y, Yoshimura M, Yasue H, et al.: Aldosterone production is activated in failing ventricle in humans. Circulation 2001, 103:72\u201377.","journal-title":"Circulation"},{"key":"1_CR18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1161\/01.HYP.0000015905.27598.E9","volume":"39","author":"N Yamamoto","year":"2002","unstructured":"Yamamoto N, Yasue H, Mizuno Y, et al.: Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension 2002, 39:958\u2013962.","journal-title":"Hypertension"},{"key":"1_CR19","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1172\/JCI117269","volume":"93","author":"M Young","year":"1994","unstructured":"Young M, Fullerton M, Dilley R, Funder J: Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994, 93:2578\u20132583.","journal-title":"J Clin Invest"},{"key":"1_CR20","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1161\/01.CIR.94.11.2756","volume":"94","author":"F Diet","year":"1996","unstructured":"Diet F, Pratt RE, Berry GJ, et al.: Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996, 94:2756\u20132767.","journal-title":"Circulation"},{"key":"1_CR21","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/01.CIR.103.3.448","volume":"3","author":"D Weiss","year":"2001","unstructured":"Weiss D, Kools JJ, Taylor WR: Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001, 3:448\u2013454.","journal-title":"Circulation"},{"key":"1_CR22","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/hc0402.102619","volume":"105","author":"G Nickenig","year":"2002","unstructured":"Nickenig G, Harrison DG: The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 2002, 105:530\u2013536.","journal-title":"Circulation"},{"key":"1_CR23","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1172\/JCI7818","volume":"105","author":"A Daugherty","year":"2000","unstructured":"Daugherty A, Manning MW, Cassis LA: Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000, 105:1605\u20131612.","journal-title":"J Clin Invest"},{"key":"1_CR24","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1161\/01.RES.84.6.695","volume":"84","author":"Y Han","year":"1999","unstructured":"Han Y, Runge MS, Brasier AR: Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factorkappa B transcription factors. Circ Res 1999, 84:695\u2013703.","journal-title":"Circ Res"},{"key":"1_CR25","first-page":"1629","volume":"19:1623","author":"R Kranzhofer","year":"2000","unstructured":"Kranzhofer R, Schmidt J, Pfeiffer CAH, et al.: Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000, 19:1623:1629.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1_CR26","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/01.CIR.100.11.1223","volume":"100","author":"PE Tummala","year":"1999","unstructured":"Tummala PE, Chem XL, Sundell CL, et al.: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature. A potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999, 100:1223\u20131229.","journal-title":"Circulation"},{"key":"1_CR27","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1161\/01.RES.83.9.952","volume":"83","author":"XL Chen","year":"1998","unstructured":"Chen XL, Tummala PE, Olbrych MT, et al.: Angiotensin II induces monocyte chemoattractant protein-1 gene in rat vascular smooth muscle cells. Circ Res 1998, 83:952\u2013959.","journal-title":"Circ Res"},{"key":"1_CR28","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1357-2725(02)00271-6","volume":"35","author":"Y Suzuki","year":"2003","unstructured":"Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al.: Inflammation and angiotensin II. Int J Biochem Cell Biol 2003, 35:881\u2013900.","journal-title":"Int J Biochem Cell Biol"},{"key":"1_CR29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1523-1755.2000.00160.x","volume":"58","author":"S Nakamura","year":"2000","unstructured":"Nakamura S, Nakamura I, Ma L, et al.: Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000, 58:251\u2013259.","journal-title":"Kidney Int"},{"key":"1_CR30","first-page":"419","volume":"45","author":"NJ Brown","year":"2000","unstructured":"Brown NJ, Vaughan DE: Prothrombotic effects of angiotensin. Adv Intern Med 2000, 45:419\u2013429.","journal-title":"Adv Intern Med"},{"key":"1_CR31","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1172\/JCI117809","volume":"95","author":"DE Vaughan","year":"1995","unstructured":"Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995, 95:995\u20131001.","journal-title":"J Clin Invest"},{"key":"1_CR32","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1161\/01.CIR.95.12.2643","volume":"95","author":"MA Pfeffer","year":"1997","unstructured":"Pfeffer MA, Greaves SC, Arnold JMO, et al.: Early vs. delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction: the Healing and Early Afterload Reducing Therapy trial. Circulation 1997, 95:2643\u20132651.","journal-title":"Circulation"},{"key":"1_CR33","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1161\/01.CIR.101.13.1586","volume":"101","author":"WB Strawn","year":"2000","unstructured":"Strawn WB, Chappell MC, Dean RH, et al.: Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000, 101:1586\u20131593.","journal-title":"Circulation"},{"key":"1_CR34","first-page":"IV9","volume":"23","author":"B Pitt","year":"2000","unstructured":"Pitt B: The anti-ischemic potential of angiotensinconverting enzyme inhibition: insights from the heart outcomes prevention evaluation trial. Clin Cardiol 2000, 23:IV9-IV14.","journal-title":"Clin Cardiol"},{"key":"1_CR35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145\u2013153.","journal-title":"N Engl J Med"},{"key":"1_CR36","doi-asserted-by":"crossref","unstructured":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group [no authors listed].N Engl J Med 1987, 316:1429\u20131435.","DOI":"10.1056\/NEJM198706043162301"},{"key":"1_CR37","doi-asserted-by":"crossref","unstructured":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators [no authors listed]. N Engl J Med 1991, 325:293\u2013302.","DOI":"10.1056\/NEJM199108013250501"},{"key":"1_CR38","doi-asserted-by":"crossref","unstructured":"Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators [no authors listed]. N Engl J Med 1992, 327:685\u2013691.","DOI":"10.1056\/NEJM199209033271003"},{"key":"1_CR39","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","volume":"100","author":"M Packer","year":"1999","unstructured":"Packer M, Poole-Wilson PA, Armstrong PW, et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure: ATLAS Study Group. Circulation 1999, 100:2312\u20132318.","journal-title":"Circulation"},{"key":"1_CR40","unstructured":"Heart Failure Society of America: HFSA Practice Guidelines: Guidelines for Management of Patients With Heart Failure Caused by Left Ventricular Systolic Dysfunction-Pharmacological Approaches. http:\/\/www.hfsa.org\/pdf\/lvsd_heart_failure.pdf.Accessed August 7, 2004."},{"key":"1_CR41","volume-title":"Drug Topics Red Book","year":"2003","unstructured":"Drug Topics Red Book. Edited by Cohen HE. Montvale, NJ: Thomson PDR; 2003."},{"key":"1_CR42","doi-asserted-by":"crossref","unstructured":"GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza Nell\u2019infarto Miocardico [no authors listed]. Lancet 1994, 343:1115\u20131122.","DOI":"10.1016\/S0140-6736(94)90232-1"},{"key":"1_CR43","doi-asserted-by":"crossref","unstructured":"ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Fourth International Study of Infarct Survival (ISIS-4) Collaborative Group [no authors listed]. Lancet 1995, 345:669\u2013685.","DOI":"10.1016\/S0140-6736(95)90865-X"},{"key":"1_CR44","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","volume":"327","author":"MA Pfeffer","year":"1992","unstructured":"Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992, 327:669\u2013677.","journal-title":"N Engl J Med"},{"key":"1_CR45","doi-asserted-by":"crossref","unstructured":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators [no authors listed]. Lancet 1993, 342:821\u2013828.","DOI":"10.1016\/0140-6736(93)92693-N"},{"key":"1_CR46","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","volume":"333","author":"L Kober","year":"1995","unstructured":"Kober L, Torp-Pedersen C, Carlsen JE, et al.: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995, 333:1670\u20131676.","journal-title":"N Engl J Med"},{"key":"1_CR47","unstructured":"American College of Cardiology Foundation and the American Heart Association, Inc.: ACC\/AHA Practice Guidelines-Full Text: ACC\/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction. http:\/\/www.acc.org\/clinical\/guidelines\/stemi\/index.pdf. Accessed August 7, 2004."},{"key":"1_CR48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0002-9343(00)00579-9","volume":"109","author":"BM Massie","year":"2000","unstructured":"Massie BM, Teerlink JR: Interaction between aspirin and angiotensin-converting enzyme inhibitors: real or imagined. Am J Med 2000, 109:431\u2013433.","journal-title":"Am J Med"},{"key":"1_CR49","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0735-1097(97)00502-0","volume":"1","author":"AS Al-Khadra","year":"1998","unstructured":"Al-Khadra AS, Salem DN, Rand WM, et al.: Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial. J Am Coll Cardiol 1998, 1:419\u2013425.","journal-title":"J Am Coll Cardiol"},{"key":"1_CR50","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0002-9343(00)00492-7","volume":"109","author":"JG Peterson","year":"2000","unstructured":"Peterson JG, Topol EJ, Sapp SK, et al.: Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med 2000, 109:371\u2013377. A concise and balanced perspective on this common clinical question.","journal-title":"Am J Med"},{"key":"1_CR51","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","volume":"355","author":"B Pitt","year":"2000","unstructured":"Pitt B, Segal R, Martinez FA, et al.: Randomized trial of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study (ELITE II). Lancet 2000, 355:1582\u20131587.","journal-title":"Lancet"},{"key":"1_CR52","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure (Val-HeFT). N Engl J Med 2001, 345:1667\u20131675.","journal-title":"N Engl J Med"},{"key":"1_CR53","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0735-1097(02)02304-5","volume":"40","author":"AP Maggioni","year":"2002","unstructured":"Maggioni AP, Anand I, Gottlieb SO, et al.: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002, 40:1414\u20131421.","journal-title":"J Am Coll Cardiol"},{"key":"1_CR54","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","volume":"362","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on morbidity and mortality in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759\u2013766.","journal-title":"Lancet"},{"key":"1_CR55","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893\u20131906.","journal-title":"N Engl J Med"},{"key":"1_CR56","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure: randomized aldactone evaluation study investigators. N Engl J Med 1999, 341:709\u2013717.","journal-title":"N Engl J Med"},{"key":"1_CR57","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543\u2013551.","journal-title":"N Engl J Med"},{"key":"1_CR58","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309\u20131321.","journal-title":"N Engl J Med"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-005-0001-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-005-0001-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-005-0001-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:52:31Z","timestamp":1559436751000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-005-0001-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["1"],"URL":"https:\/\/doi.org\/10.1007\/s11936-005-0001-7","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}